294 related articles for article (PubMed ID: 25284154)
1. Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.
Sun X; Hasanali ZS; Chen A; Zhang D; Liu X; Wang HG; Feith DJ; Loughran TP; Xu K
Br J Haematol; 2015 Feb; 168(3):371-83. PubMed ID: 25284154
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA.
Lunke S; Maxwell S; Khurana I; K N H; Okabe J; Al-Hasani K; El-Osta A
Clin Epigenetics; 2021 Mar; 13(1):58. PubMed ID: 33743782
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Richon VM; Sandhoff TW; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation.
Dudakovic A; Evans JM; Li Y; Middha S; McGee-Lawrence ME; van Wijnen AJ; Westendorf JJ
J Biol Chem; 2013 Oct; 288(40):28783-91. PubMed ID: 23940046
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
Fröhlich LF; Mrakovcic M; Smole C; Lahiri P; Zatloukal K
PLoS One; 2014; 9(3):e91558. PubMed ID: 24618889
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
Gillenwater AM; Zhong M; Lotan R
Mol Cancer Ther; 2007 Nov; 6(11):2967-75. PubMed ID: 18025281
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro.
Abou Najem S; Khawaja G; Hodroj MH; Rizk S
Curr Mol Pharmacol; 2019; 12(4):281-300. PubMed ID: 30868973
[TBL] [Abstract][Full Text] [Related]
12. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
Yerbes R; López-Rivas A
Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
[TBL] [Abstract][Full Text] [Related]
13. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Ji J; Valdez BC; Li Y; Liu Y; Teo EC; Nieto Y; Champlin RE; Andersson BS
Exp Hematol; 2016 Jun; 44(6):458-65. PubMed ID: 26976752
[TBL] [Abstract][Full Text] [Related]
14. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
[TBL] [Abstract][Full Text] [Related]
18. Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition.
King K; Hauser AT; Melesina J; Sippl W; Jung M
Molecules; 2018 Feb; 23(2):. PubMed ID: 29393896
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Zhou X; Yang XY; Popescu NC
Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
